BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Dec 19, 2011
 |  BioCentury  |  Analyst Picks & Changes

Analyst Picks & Changes

Analyst Picks & Changes

Company Bank Analyst Coverage Opinion Wk chg 12/16 cls
BioSante Pharmaceuticals Inc. (NASDAQ:BPAX) Jefferies Graig Suvannavejh Downgrade Hold (from buy) -82% $0.45
Leerink Joseph Schwartz Downgrade Market perform (from market outperform)
McNicoll, Lewis & Vlak Christopher James Downgrade Hold (from buy)
Rodman Elemer Piros Downgrade Market perform (from market outperform)
Suvannavejh also lowered his target to $0.70 from $5 after top-line data showed that LibiGel transdermal testosterone gel missed the co-primary endpoints vs. placebo in the Phase III BLOOM-1 and BLOOM-2 trials to treat hypoactive sexual...

Read the full 809 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >